Cargando…

Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast

AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Edaise M, Beca, Francisco, Sebastiao, Ana Paula Martins, Murray, Melissa P, Silveira, Catarina, Da Cruz Paula, Arnaud, Pareja, Fresia, Wen, Hannah Y, D'Alfonso, Timothy M, Edelweiss, Marcia, Weigelt, Britta, Brogi, Edi, Reis-Filho, Jorge S, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260148/
https://www.ncbi.nlm.nih.gov/pubmed/33376197
http://dx.doi.org/10.1136/jclinpath-2020-207062
_version_ 1783718770208931840
author da Silva, Edaise M
Beca, Francisco
Sebastiao, Ana Paula Martins
Murray, Melissa P
Silveira, Catarina
Da Cruz Paula, Arnaud
Pareja, Fresia
Wen, Hannah Y
D'Alfonso, Timothy M
Edelweiss, Marcia
Weigelt, Britta
Brogi, Edi
Reis-Filho, Jorge S
Zhang, Hong
author_facet da Silva, Edaise M
Beca, Francisco
Sebastiao, Ana Paula Martins
Murray, Melissa P
Silveira, Catarina
Da Cruz Paula, Arnaud
Pareja, Fresia
Wen, Hannah Y
D'Alfonso, Timothy M
Edelweiss, Marcia
Weigelt, Britta
Brogi, Edi
Reis-Filho, Jorge S
Zhang, Hong
author_sort da Silva, Edaise M
collection PubMed
description AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. RESULTS: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. CONCLUSIONS: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms.
format Online
Article
Text
id pubmed-8260148
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82601482022-02-07 Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast da Silva, Edaise M Beca, Francisco Sebastiao, Ana Paula Martins Murray, Melissa P Silveira, Catarina Da Cruz Paula, Arnaud Pareja, Fresia Wen, Hannah Y D'Alfonso, Timothy M Edelweiss, Marcia Weigelt, Britta Brogi, Edi Reis-Filho, Jorge S Zhang, Hong J Clin Pathol Short Report AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. RESULTS: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. CONCLUSIONS: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms. BMJ Publishing Group 2022-02 2020-12-29 /pmc/articles/PMC8260148/ /pubmed/33376197 http://dx.doi.org/10.1136/jclinpath-2020-207062 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Report
da Silva, Edaise M
Beca, Francisco
Sebastiao, Ana Paula Martins
Murray, Melissa P
Silveira, Catarina
Da Cruz Paula, Arnaud
Pareja, Fresia
Wen, Hannah Y
D'Alfonso, Timothy M
Edelweiss, Marcia
Weigelt, Britta
Brogi, Edi
Reis-Filho, Jorge S
Zhang, Hong
Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title_full Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title_fullStr Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title_full_unstemmed Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title_short Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
title_sort stromal med12 exon 2 mutations in complex fibroadenomas of the breast
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260148/
https://www.ncbi.nlm.nih.gov/pubmed/33376197
http://dx.doi.org/10.1136/jclinpath-2020-207062
work_keys_str_mv AT dasilvaedaisem stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT becafrancisco stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT sebastiaoanapaulamartins stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT murraymelissap stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT silveiracatarina stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT dacruzpaulaarnaud stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT parejafresia stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT wenhannahy stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT dalfonsotimothym stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT edelweissmarcia stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT weigeltbritta stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT brogiedi stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT reisfilhojorges stromalmed12exon2mutationsincomplexfibroadenomasofthebreast
AT zhanghong stromalmed12exon2mutationsincomplexfibroadenomasofthebreast